Insmed Incorporated
Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About INSM
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline.
INSM Key Statistics
Stock Snapshot
The current Insmed Incorporated(INSM) stock price is $200.33, with a market capitalization of 42.73B. The stock trades at a price-to-earnings (P/E) ratio of -31.86.
On 2025-12-16, Insmed Incorporated(INSM) stock traded between a low of $192.50 and a high of $201.49. Shares are currently priced at $200.33, which is +4.1% above the low and -0.6% below the high.
The Insmed Incorporated(INSM)'s current trading volume is 550.36K, compared to an average daily volume of 2.46M.
In the last year, Insmed Incorporated(INSM) shares hit a 52-week high of $212.75 and a 52-week low of $60.40.
In the last year, Insmed Incorporated(INSM) shares hit a 52-week high of $212.75 and a 52-week low of $60.40.
INSM News
Cantor Fitzgerald raised the firm’s price target on Insmed (INSM) to $230 from $216 and keeps an Overweight rating on the shares. The firm views the brensocatib...
Below is Validea's guru fundamental report for INSMED INC (INSM). Of the 22 guru strategies we follow, INSM rates highest using our Twin Momentum Investor model...
Nasdaq announced the results of the annual reconstitution of the Nasdaq-100 Index, which will become effective prior to market open on Monday, December 22, 2025...
Analyst ratings
95%
of 20 ratingsMore INSM News
Insmed was recently added to the Nasdaq-100 Index and has seen continued accumulation by prominent institutional investor Stanley Druckenmiller, while Director...
Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks Quick Read Natera (NTRA) grew revenue 34.66% year-over-year in Q3 2025 and has rall...
TD Cowen raised the firm’s price target on Insmed (INSM) to $269 from $231 and keeps a Buy rating on the shares. The firm called it a Best Idea for four reasons...
If you are looking at Insmed and wondering whether the huge run up has already priced in the story, you are not alone. This article will walk through what the n...
New insider activity at Insmed ( (INSM) ) has taken place on December 9, 2025. TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insight...